1. Home
  2. Analysis
  3. Simvastatin
  4. Inrebic

Simvastatin and Inrebic drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Simvastatin (simvastatin) and Inrebic (fedratinib hydrochloride). Common drug interactions include cardiac disorder among females and platelet count decreased among males.

The phase IV clinical study analyzes what interactions people have when they take Simvastatin and Inrebic. It is created by eHealthMe based on reports of 16 people who take the same drugs from the FDA, and is updated regularly.

What is Simvastatin?

Simvastatin has active ingredients of simvastatin. It is often used in high blood cholesterol. eHealthMe is studying from 256,969 Simvastatin users. Check the latest studies of Simvastatin.

What is Inrebic?

Inrebic has active ingredients of fedratinib hydrochloride. eHealthMe is studying from 1,138 Inrebic users. Check the latest studies of Inrebic.

On Jul, 09, 2026

16 people who take Simvastatin and Inrebic together, and have interactions are studied.

Simvastatin and Inrebic drug interactions.

What are the common drug interactions of Simvastatin and Inrebic, by gender? *:

female:

  1. Cardiac disorder
  2. Death
  3. Dyspnoea (difficult or laboured respiration)
  4. Haemoglobin decreased
  5. Skin irritation
  6. Urinary tract infection

male:

  1. Platelet count decreased
  2. Anxiety
  3. Haemoglobin decreased
  4. Splenomegaly (enlargement of spleen)
  5. White blood cell count decreased
  6. Affective disorder (mental disorder)
  7. Drug intolerance (drug sensitivity)
  8. Fatigue (feeling of tiredness)
  9. Increased tendency to bruise (increased tendency to injure the underlying soft tissue or bone)
  10. Muscle spasms (muscle contraction)

What are the common drug interactions of Simvastatin and Inrebic, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

  1. Platelet count decreased
  2. Anxiety
  3. White blood cell count decreased
  4. Affective disorder (mental disorder)
  5. Confusional state
  6. Disorientation (disability in which the senses of time, direction, and recognition of people and places)
  7. Dyspnoea (difficult or laboured respiration)
  8. Skin irritation
  9. Catheter site haemorrhage (bleeding at catheter site)
  10. Haematoma (collection of blood outside the blood vessels)

What are the existing conditions these people have? *

  1. Primary Myelofibrosis (primary disorder of the bone marrow): 5 people, 31.25%
  2. Sleep Disorder: 2 people, 12.50%
  3. Depression: 2 people, 12.50%

* Approximation only. Some reports may have incomplete information.

Do you take Simvastatin and Inrebic?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Simvastatin and Inrebic:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Simvastatin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Inrebic:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Simvastatin and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Inrebic and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on simvastatin and fedratinib hydrochloride (the active ingredients of Simvastatin and Inrebic, respectively), and Simvastatin and Inrebic (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.